Immunocore is a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases.
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4 (MAGE-A4), ADP-A2M10 (MAGE-A10), and ADP-A2AFP (AFP)) in multiple solid tumor indications. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The foundation of our TCR therapies is the work we did with NY-ESO SPEAR T-cells, which we transitioned to GSK in 2018, showing responses in two solid tumors and treating more than 90 patients in six different indications.
“I’ve had the pleasure of working with Aigenpulse for the past year.
Aigenpulse is an extraordinary data management and analytics platform that enables us to efficiently
streamline processes and place an even greater focus on research.”
“Aigenpulse enables my team access to all of our research data, coherently structured, integrated and linked across the organisation from one easy to use interface.”
Are you ready to unlock the power of your data?
Speak to one of our scientists to discuss how The Aigenpulse Platform can accelerate, augment and empower your drug discovery.